drugset / Trial / NCT04126655

Modelle 001, TS-inhibition in Colorectal Liver Metastases Comparing Arfolitixorin and Calciumfolinate

NCT04126655

Phase 1/2 Unknown 30 enrolled Vastra Gotaland Region Isofol Medical AB · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

A study that is blinded to the patient and the investigator where the combination of Arfolitixorin + 5-FU is compared to Calciumfolinate + 5-FU. The patients will be randomised and will receive the above described combination as IV bolus injections, peroperatively in conjuction with collection of the first tissue sample. A low dose (30 mg) and a high dose (120) mg of Arfolitixorin will be used in order to investigate the relation between dose of Arfolitixorin and TS-inhibition.

Timeline

Start
2020-02-05
Primary completion
2021-10
Completion
2021-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Arfolitixorin Small molecule 30 mg/m2 Intravenous
Subject Arfolitixorin Small molecule 120 mg/m2 Intravenous
Subject Leucovorin Small molecule 60 mg/m2 Intravenous
Background fluorouracil Small molecule 250 mg/m2 Intravenous

Indications